FDA warns of cardiac reactions with Harvoni, Sovaldi drug combinations

The FDA approved the changes to the Harvoni (ledipasvir/sofosbuvir, Gilead Sciences) fixed- dose and Sovaldi (sofosbuvir) labels to update the Warnings and Precautions, Adverse Reactions and Drug Interactions sections, after nine serious cases of symptomatic bradycardia and one fatal cardiac arrest were reported among patients taking amiodarone and Harvoni or amiodarone and sofosbuvir in combination with another direct-acting antiviral (DAA), according to the release. Read more: bit.ly/1HsHHuy

oldestnewest

You may also like...